Immunic focusing on business development during Q4
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a...
Stay updated with breaking news from Progressive Multiple. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a...
Immunic Inc President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a third-quarter update.Dr Vitt starts by describing the...
Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P...
Researchers use an established murine model of cortical inflammatory demyelination to investigate the effects of vitamin D.
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today...